SCHEMBL24281158

SCHEMBL24281158

O=C1Nc2c(F)cccc2C1(O)c1ccccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.44
MEN1 O00255 1/20 0.44
AKR1B1 P15121 2/20 0.42
PDE7A Q13946 1/20 0.42
POLB P06746 1/20 0.41
CASP6 P55212 1/20 0.41
AKR1A1 P14550 1/20 0.38
PDK2 Q15119 3/20 0.37
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA7 P43166 2/20 0.36
CA9 Q16790 2/20 0.36
CA12 O43570 1/20 0.36
CA4 P22748 1/20 0.36
HDAC4 P56524 2/20 0.35
HCAR2 Q8TDS4 1/20 0.34
CNR1 P21554 1/20 0.33
HTT P42858 1/20 0.33
GPR35 Q9HC97 1/20 0.33
GPR55 Q9Y2T6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24281881 0.87 CNR1 (0.48) KMT2AMEN1AKR1B1PDE7APOLB
SCHEMBL24281876 0.87 KMT2A (0.40) KMT2AMEN1AKR1B1PDE7APOLB
SCHEMBL11734265 0.87 POLB (0.46) KMT2AMEN1AKR1B1PDE7APOLB
SCHEMBL24281077 0.84 KMT2A (0.56) KMT2AMEN1POLBCASP6PDK2
SCHEMBL24281127 0.84 KMT2A (0.37) KMT2AMEN1AKR1B1PDE7APOLB
SCHEMBL24280992 0.81 KMT2A (0.67) KMT2AMEN1POLBCASP6PDK2
SCHEMBL11042580 0.80 POLB (0.44) KMT2AMEN1AKR1B1POLBCASP6
SCHEMBL24281322 0.78 KMT2A (0.50) KMT2AMEN1AKR1B1POLBCASP6
SCHEMBL24281060 0.77 AKR1B1 (0.36) KMT2AMEN1AKR1B1PDE7APOLB
SCHEMBL11730433 0.77 AKR1B1 (0.47) KMT2AMEN1AKR1B1PDE7APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018103-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST RAQUALIA PHARMA INC. (JP) 2024-01-18 US disclosed
US-20240018103-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST RAQUALIA PHARMA INC. (JP) 2024-01-18 US disclosed
WO-2022071484-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST RAQUALIA PHARMA INC. (JP) 2022-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018103-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST CRHR2, CRHR1, CRH KMT2A 4117/4885MEN1 1996/4885AKR1B1 743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.